Mayinglong Pharmaceutical Group (600993) Fundamentals 2026 — P/E 17.1x, Revenue Analysis | SniperIQ
Mayinglong Pharmaceutical Group (600993) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥10.1B, trading at ¥23.47 on the SHH. This SniperIQ fundamentals page covers Mayinglong Pharmaceutical Group's valuation (P/E 17.1x, P/B 2.2x), profitability (net margin 15.1%), revenue (¥3.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Mayinglong Pharmaceutical Group's market cap?
Mayinglong Pharmaceutical Group (600993) has a market capitalization of approximately ¥10.1B, trading at ¥23.47 on the SHH. Market cap moves with the live share price.
What is Mayinglong Pharmaceutical Group's P/E ratio?
Mayinglong Pharmaceutical Group's trailing twelve-month P/E ratio is 17.1x, with a price-to-book (P/B) of 2.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Mayinglong Pharmaceutical Group?
Mayinglong Pharmaceutical Group runs a net profit margin of 15.1%, a gross margin of 48.8%, and an operating margin of 18.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Mayinglong Pharmaceutical Group generate?
Mayinglong Pharmaceutical Group reported revenue of ¥3.9B for fiscal year 2025, with net income of ¥581M and earnings per share (EPS) of 1.35. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Mayinglong Pharmaceutical Group pay a dividend?
Mayinglong Pharmaceutical Group offers a trailing dividend yield of about 2.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Mayinglong Pharmaceutical Group financially healthy?
Mayinglong Pharmaceutical Group carries a debt-to-equity ratio of 0.02x and a current ratio of 5.06x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Mayinglong Pharmaceutical Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Mayinglong Pharmaceutical Group (600993) the key facts are: market cap ¥10.1B, P/E 17.1x, revenue ¥3.9B, 52-week range 21.22-30.18. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Mayinglong Pharmaceutical Group's full fundamentals live
Get Mayinglong Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.